Cipla Ltd

- Shareholder Jaydeep Bakshi inquired about the company's future capital expenditure (capex) plans and growth programs, including R&D investments and new product development pipeline. However, no specific detailed response or commitment on new fundraising through debt or equity is provided in the transcript. - Several shareholders expressed general support for the company’s growth and dividend, but there are no explicit mentions of any ongoing or planned equity or debt fundraising. - One shareholder suggested the possibility of bonus shares to keep capital comfortable and reduce borrowings, indicating an interest in capital structure optimization, but no official plan was disclosed. - No concrete details on new fundraising through debt or equity are available from the provided pages.

- Shareholder Jaydeep Bakshi inquired about future capex programs and growth plans, including R&D investment for new product development (Page 33). - Another shareholder, Hariram Chaudhary, also asked about capital expenditure spent during FY 2022-23 and plans for FY 2023-24 (Page 26). - A request for information on new technologies adopted and capital expenditure was made to highlight innovation and digital adoption (Page 26). - However, no specific details or figures regarding current or future capex, strategic, or capital investments were directly provided or disclosed in the available transcript sections from the annual meeting on these pages. - The company's focus on launching new products and growth prospects was acknowledged but precise capex plans remain unspecified in the discussed excerpts.

- The company has demonstrated excellent year-on-year revenue growth, reflecting a strong sales performance. - Future growth plans include continued focus on expanding global market presence, as shareholders inquired about revenue from the global sector. - There is emphasis on launching new products and advancing R&D pipelines to sustain growth momentum. - Capex programs are planned for new drug development, promotional tie-ups, and innovation in product offerings. - Shareholders expressed interest in planned capital expenditure for 2023-24 to support expansion. - The company aims to maintain and grow its market leadership, particularly in generic medicines and respiratory segments. - Debt recovery and financial stability are being monitored to support sustainable growth. - Engagement with shareholders and potential factory visits indicate efforts to strengthen stakeholder relations alongside growth.

- Consistent year-on-year revenue growth with excellent performance highlighted by shareholders. - Net profit for the year reached INR 2,513 crores standalone and INR 2,832 crores consolidated, showing strong profitability. - First quarter results for 2023-24 showed revenue of INR 4,318 crores and net profit of INR 895 crores, indicating robust quarterly performance. - Shareholder Jaydeep Bakshi expressed confidence in sustained growth and inquired about future capex and R&D plans, signaling company focus on expansion and innovation. - Shareholders encourage bonus shares and better capital management to strengthen financial position and reduce borrowings. - The company plans to continue launching new products; 81 new products in recent years have contributed to growth. - Commitment to maintaining and growing the global market, including revenue from international sectors, is stressed. - Overall, prospects indicate sound and sustainable growth in earnings and EPS in the coming years.

The transcript provided from the PDF (page 34 and surrounding pages) does not specifically mention Cipla's current or expected order book or pending orders. Shareholders' questions and comments focus on topics such as: - Future capex and growth plans - Revenue from global markets - New product pipeline and R&D expenditure - Dividend performance - Legal dispute cases - Demat and shareholder services - Renewable energy and CSR initiatives No explicit details about current or expected order book or pending orders are discussed or disclosed in the text on these pages.